EGFR and cancer: MUC1 and galectin-3 are both commonly over-expressed by solid tumours and their interactive effects on EGFR activation may have an important influence on EGFR-mediated tumourigenesis and cancer progression, and on the effectiveness of EGFR-targeted therapy.